Impact of new systemic therapies in overall survival in non-metastatic castration resistant prostate cancer: systematic review and meta-analysis

Prostate cancer is the most frequent genitourinary tumor worldwide, with almost 1,500,000 new cases diagnosed annually1. Since the 1940s, androgen deprivation therapy (ADT) has been the backbone treatment for advanced prostate cancer2. Nevertheless, many patients on continuous ADT experience disease progression despite castrate levels of testosterone, transitioning to a disease stage known as “castration-resistant”.